AGELAN

Main information

  • Trade name:
  • AGELAN Tablets 2.5 Milligram
  • Dosage:
  • 2.5 Milligram
  • Pharmaceutical form:
  • Tablets
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • AGELAN Tablets 2.5 Milligram
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0073/102/001
  • Authorization date:
  • 24-02-1988
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

AgelanTablets2.5mg

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontainsindapamidehemihydrate2.5mg.

Forafulllistofexcipients,see6.1.

3PHARMACEUTICALFORM

Sugar-coatedtablets.

Pink,circular,sugarcoatedtablets.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Treatmentofessentialhypertension.

4.2Posologyandmethodofadministration

Agelantabletsarefororaladministration,only.

Adults:2.5mg(1tablet)dailytakeninthemorning.Thisdoseshouldnotbeexceededasthereisnoadditional

antihypertensiveeffect.Ifbloodpressureisnotcontrolled,thenanantihypertensiveagentofanotherclassshouldbe

used.

Elderly:Indapamidemayhaveamoreprolongedeliminationtime.Sincetheelderlyaremoresusceptibletoelectrolyte

imbalanceandfluidlossitisadvisabletomonitorthesepatientsfrequentlyforevidenceofsucheffects.

4.3Contraindications

Useinpatientswithsevereimpairmentofhepaticfunction,orseveredegreesofrenalinsufficiency.

Useinpatientswithhypokalaemia.

Useinpatientshypersensitivetotheactiveingredient.

4.4Specialwarningsandprecautionsforuse

Patientswhoarebeingtreatedwiththispreparationrequireregularsupervisionwithmonitoringoffluidandelectrolyte

statetoavoidinadequatepotassiumsupplementationorexcessivelossoffluid.

Thepreparationshouldonlybeusedwithparticularcautioninelderlypatientsorthosewithpotentialobstructionofthe

urinarytract,orwithdisordersrenderingtheirelectrolytebalanceprecarious.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/04/2010 CRN 2080835 page number: 1

adjustmentofcontrolofhypoglycaemicagentsincasesofdiabetesmellitus.

Aswithallantihypertensiveagents,acautiousdosagescheduleisindicatedinpatientswithseverecoronaryorcerebral

arteriosclerosisorrecentcerebrovascularaccident.

Inpatientswithhyperlipidaemia,serumlipidsshouldbemonitoredregularly.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Whenusedincombinationwithotherantihypertensivedrugs,thedosageoftheselattermayrequirereduction.

Agelanmaypotentiatetheactionofdiuretics,andwhenusedincombinationwiththesedrugs,theremaybeaneedfor

potassiumsupplementation.

Concurrentusewithlithiumtherapymayincreasetoxicityofthelatterduetoincreasedbloodlevelsandaparadoxical

anti-diureticeffect.

Diureticinducedhypokalaemiamaybeaggravatedbycorticosteroids,ACTH,carbenoxolone,amphotericinB.

Diureticandanti-hypertensiveeffectswillbediminishedbyconcurrentuseofnon-steroidalanti-inflammatorydrugs.

Deteriorationinrenalfunctionmayalsooccur.

Diureticspotentiatetheactionofcurarederivativesandantihypertensivedrugs(e.g.guanethidine,methyldopa,beta-

blockers,vasodilators,calciumantagonistsandACEinhibitors).

4.6Pregnancyandlactation

Agelanshouldnotberecommendedforuseduringthefirsttrimesterofpregnancyorduringlactationunlessthe

physicianconsidersitnecessary.Teratogenicstudiesinanimalshaveshownnoadverseeffectsbutexperienceofuse

inpregnantpatientsislimited.

4.7Effectsonabilitytodriveandusemachines

Noneknown.

4.8Undesirableeffects

Sideeffectsincludemusclecramps,fatigue,allergicreactions,especiallyskinlesionsandsyncope.Hypokalaemiamay

occur,lessfrequentlyhyperuricaemia.

4.9Overdose

Possiblesignsofoverdosageincludeelectrolyteimbalance,hypotension,gastrointestinaldisturbanceandmuscular

weakness.Thereisnospecificantidotetoindapamideandtreatmentofoverdosageissymptomaticandsupportive.

Thestomachmaybeemptiedbyemesisorbygastricaspirationandlavage.Particularattentionshouldbepaidto

correctinganyelectrolyteabnormalities.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Agelantabletscontainindapamide,anon-thiazideindolederivativeofchlorosulphonamide.Attherapeuticdoses,

indapamideinducessomemilddiureticeffect.Indapamidehasbeenshowntodecreasevascularsmoothmuscle

reactivityandperipheralresistance.Indosesof2.5mgdaily,indapamaidehasbeenshowntoexertanantihypertensive

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/04/2010 CRN 2080835 page number: 2

antihypertensiveeffect.

5.2Pharmacokineticproperties

Indapamideisrapidlyandcompletelyabsorbedfromthegastro-intestinaltract.Itispreferentiallyandreversiblytaken

upbycirculatingerythrocytesandabout71to79%ofthedrugisboundtoplasmaproteins.Indapamidehasaterminal

half-lifeofabout14hours.Itisextensivelymetabolised.About70%ofanoraldoseisexcretedviathekidneysand

about23%bythegastrointestinaltract.

5.3Preclinicalsafetydata

NofurtherrelevantinformationotherthanthatwhichisincludedintheothersectionsoftheSummaryofProduct

Characteristics.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

LactoseMonohydrate

CalciumHydrogenPhosphateDihydrate

MaizeStarch

MagnesiumStearate

CroscarmelloseSodium

Talc

Shellac

CastorOil

TitaniumDioxide(E171)

Sucrose

Methylparahydroxybenzoate

Propylparahydroxybenzoate

Acacia

OpaluxAS-F-1312andmacrogol6000

OpaluxconsistsofsucroseBP,purifiedwater,sodiumbenzoate,polyvinylpyrrolidone,talc,titaniumdioxide,ponceau

4Raluminiumlake(E124),erythrosinealuminiumlake(E127).

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

3years.

6.4Specialprecautionsforstorage

Donotstoreabove25 o

Storeinadryplace.

Storeintheoriginalpackageinordertoprotectfromlight.

6.5Natureandcontentsofcontainer

BlisterpackswhichconsistofstripsmadefromhardPVCwithafoillid.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/04/2010 CRN 2080835 page number: 3

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

None.

7MARKETINGAUTHORISATIONHOLDER

AntigenPharmaceuticalsLimited

Roscrea,Co.Tipperary

Ireland

8MARKETINGAUTHORISATIONNUMBER

PA0073/102/001

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:25February1988

Dateoflastrenewal: 25February2008

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/04/2010 CRN 2080835 page number: 4